| [1］Yu Xu，Limin Wang，Jiang He，et al.For the 2010 China Noncommunicable Disease Surveillance Group.Prevalence and Control of Diabetes in Chinese［J］.JAMA，2013，310(9)：948-959. [2］Lee YJ，Lee YJ，Han HJ.Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells［J］.Kidney Int Suppl 2007，(106)：S27-35. [3］Gerich JE.Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus：therapeutic implications［J］.Diabet Med，2010，27(2)：136-42. [4］Rahmoune，H，Thompson PW，Ward JM，et al.Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes［J］.Diabetes 2005，54：3427-34. [5］Rossetti L，Smith D，Shulman GI，et al.Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats［J］.J Clin Invest 1987，79(5)：1510-1515. [6］Lee YJ，Lee YJ，Han HJ.Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells［J］.Kidney Int Suppl，2007，(106)：S27-35. [7］Nairs S，Wilding JP.Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus［J］.J Clin Endocrinol Metab，2010，95(1)：34-42. [8］Calado J，Sznajer Y，Metzqer D，et al.Twenty-one additional cases of familial renal glucosuria：absence of genetic heterogeneity，high prevalence of private mutations and further evidence of volume depletion［J］.Nephrol Dial Transplant，2008，23(12)：3874-3879. [9］Obermeier M，Yao M，Khanna A，et al.In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148)，a potent sodium-glucose cotransporter type Ⅱ inhibitor，in animals and humans［J］.Drug Metab Dispos，2010，38(3)：405-414. [10］Santer R，Calado J.Familial renal glucosuria and SGLT2：from a mendelian trait to a therapeutic target［J］.Clin J Am Soc Nephrol，2010，5(1)：133-141. [11］Bailey CJ，Gross JL，Pieters A，et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin：a randomised，double-blind，placebo-controlled trial［J］.Lancet，2010，26，375(9733)：2223-2233. [12］Rosenstock J，Aggarwal N，Polidori D，et al.Dose-ranging effects of canagliflozin，a sodium-glucose cotransporter 2 inhibitor，as add-on to metformin in subjects with type 2 diabetes［J］.Diabetes Care，2012，35(6)：1232-1238. [13］Liakos A，Karagiannis T，Athanasiadou E，et al.Efficacy and safety of empagliflozin for type 2 diabetes：a systematic review and meta-analysis［J］.Diabetes Obes Metab，2014，Apr 26 [14］Aylsworth A，Dean Z，VanNorman C，et al.Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus［J］.Ann Pharmacother，2014，20，48(9)：1202-1208. [15］Salsali A，et al.Reduction in postprandial glucose with dapagliflozin in type 2 diabetes.71st ADA Scientific Sessions，San Diego，24-28 June，2011［Poster 1104-P］. [16］Bailey CJ，Gross JL，Hennicken D，et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin：a randomized，double-blind，placebo-controlled 102-week trial［J］.BMC Med，2013，11：43. [17］Lavalle-González FJ，Januszewicz A，Davidson J，et al.Efficacy and safety of canagliflozin compared with placebo and sitagliptin inpatients with type 2 diabetes on background metformin monotherapy：a randomised trial［J］.Diabetologia，2013，56(12)：2582-2592. [18］Schernthaner G，Gross JL，Rosenstock J，et al.Canagliflozin Compared With Sitagliptin for PatientsWith Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea.A 52-week randomized trial.Diabetes Care Diabetes Care Publish Ahead of Print，published online April 5，2013 [19］Nauck M，et al.Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin：2-year results.71st ADA Scientific Sessions，San Diego，24-28 June，2011［Abstract 40-LB］. [20］Baker WL，Smyth LR，Riche DM，et al.Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure：a systematic review and meta-analysis［J］.J Am Soc Hypertens，2014，8(4)：262-275. [21］BMS/AZ data on file 2012，Dapagliflozin，Summary of Product characteristic. [22］Ptaszynska A，Johnsson KM，Parikh SJ，et al.Safety Profile of Dapagliflozin for Type 2 Diabetes：Pooled Analysis of Clinical Studies for Overall Safety and Rare Events［J］.Drug Saf，2014［Epub ahead of print］. [23］Parikh SJ，et al.Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria.71st ADA Scientific Sessions，San Diego，June 24-28，2011. [24］Rohwedder，et al.Dapagliflozin，a Sodium-glucose cotransporter 2 inhibitor，has a low propensity to cause hypoglycemia in patients with type 2 diabetes.71st ADA Scientific Sessions，San Diego，24-28 June，2011［Abstract 1042-P］. [25］Ferrannini E，Ramos SJ，Salsali A，et al.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise：a randomized，double-blind，placebo-controlled，phase 3 trial［J］.Diabetes Care，2010，33(10)：2217-2224. [26］Cefalu WT，Leiter LA，Yoon Efficacy and safety of canaglifl oKH，et al.zin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU)：52 week results from a randomised，double-blind，phase 3 non-inferiority trial.Lancet Published online July 12，2013 http：//dx.doi.org/10.1016/S0140-6736(13)60683 [27］FORXIGA.Summary of product characteristics.Bristol-Myers Squibb/AstraZeneca EEIG，2012. |
